Log in

NYSE:NVS - Novartis Stock Price, Forecast & News

$90.08
-6.68 (-6.90 %)
(As of 02/25/2020 02:34 AM ET)
Today's Range
$89.97
Now: $90.08
$93.67
50-Day Range
$93.70
MA: $95.66
$99.01
52-Week Range
$74.97
Now: $90.08
$99.84
Volume4.17 million shs
Average Volume1.88 million shs
Market Capitalization$206.45 billion
P/E Ratio17.84
Dividend Yield1.90%
Beta0.64
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone41-61-324-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$47.50 billion
Cash Flow$7.26 per share
Book Value$24.24 per share

Profitability

Net Income$11.73 billion

Miscellaneous

Employees103,914
Outstanding Shares2,291,800,000
Market Cap$206.45 billion
Next Earnings Date4/22/2020 (Estimated)
OptionableOptionable

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.


Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Monday, February 3rd. Stockholders of record on Wednesday, March 4th will be given a dividend of $3.0425 per share on Thursday, March 12th. This represents a dividend yield of 2%. The ex-dividend date is Tuesday, March 3rd. This is an increase from Novartis's previous annual dividend of $2.86. View Novartis' Dividend History.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its earnings results on Tuesday, October, 22nd. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.31 by $0.10. The company earned $12.17 billion during the quarter, compared to analyst estimates of $11.67 billion. Novartis had a return on equity of 23.39% and a net margin of 24.73%. The business's quarterly revenue was up 10.5% on a year-over-year basis. During the same period last year, the firm posted $1.32 earnings per share. View Novartis' Earnings History.

When is Novartis' next earnings date?

Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, April 22nd 2020. View Earnings Estimates for Novartis.

What price target have analysts set for NVS?

9 Wall Street analysts have issued 12 month target prices for Novartis' stock. Their forecasts range from $79.16 to $105.00. On average, they anticipate Novartis' share price to reach $91.67 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price. View Analyst Price Targets for Novartis.

What is the consensus analysts' recommendation for Novartis?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Has Novartis been receiving favorable news coverage?

News stories about NVS stock have trended neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novartis earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Novartis.

Are investors shorting Novartis?

Novartis saw a increase in short interest in January. As of January 31st, there was short interest totalling 3,650,000 shares, an increase of 17.7% from the January 15th total of 3,100,000 shares. Based on an average daily volume of 1,620,000 shares, the short-interest ratio is presently 2.3 days. Approximately 0.2% of the company's stock are short sold. View Novartis' Current Options Chain.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), Pfizer (PFE), Walt Disney (DIS), Intel (INTC), AT&T (T), Cisco Systems (CSCO), NVIDIA (NVDA), Merck & Co., Inc. (MRK) and Verizon Communications (VZ).

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 54)
  • Mr. Steffen Lang, Global Head of Technical Operations (Age 52)
  • Ms. Shannon Thyme Klinger, Group Gen. Counsel (Age 48)
  • Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 51)

Who are Novartis' major shareholders?

Novartis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (0.51%), Loomis Sayles & Co. L P (0.45%), Bank of America Corp DE (0.41%), Renaissance Technologies LLC (0.29%), Mawer Investment Management Ltd. (0.26%) and FMR LLC (0.26%).

Which major investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., State Street Corp, Fort Washington Investment Advisors Inc. OH, Manning & Napier Group LLC, Partner Fund Management L.P., Boston Partners and Schafer Cullen Capital Management Inc.

Which major investors are buying Novartis stock?

NVS stock was purchased by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Jennison Associates LLC, Renaissance Technologies LLC, Westfield Capital Management Co. LP, Bank of America Corp DE, Madison Asset Management LLC, Bain Capital Public Equity Management II LLC and Magnetar Financial LLC.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $90.08.

How big of a company is Novartis?

Novartis has a market capitalization of $206.45 billion and generates $47.50 billion in revenue each year. The company earns $11.73 billion in net income (profit) each year or $5.24 on an earnings per share basis. Novartis employs 103,914 workers across the globe.View Additional Information About Novartis.

What is Novartis' official website?

The official website for Novartis is http://www.novartis.com/.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]


MarketBeat Community Rating for Novartis (NYSE NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  488 (Vote Outperform)
Underperform Votes:  555 (Vote Underperform)
Total Votes:  1,043
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: What are municipal bonds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel